Pangen Biotech KRX:222110KOSDAQ
팬젠 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Pangen Biotech reported revenue of ₩4.0bn, up 13.5% year on year, and an operating loss of ₩220m. Pangen Biotech (팬젠) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Oct 26 with 1 article.
Filing signals Swung to loss Screener
Pangen Biotech quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩4.0bn | +13.5% | −₩220m margin −5.6% | −₩48m |
| Q1 2026 | ₩3.7bn | +8.4% | ₩482m margin 12.9% | ₩751m |
| Q4 2025 derived | ₩2.5bn | -42.9% | −₩404m margin −16.3% | −₩102m |
| Q3 2025 | ₩4.0bn | -12.7% | ₩377m margin 9.4% | ₩532m |
| Q2 2025 | ₩3.5bn | +53.7% | ₩833m margin 23.9% | ₩885m |
| Q1 2025 | ₩3.4bn | -1.0% | ₩701m margin 20.4% | ₩736m |
| Q4 2024 derived | ₩4.3bn | +28.0% | −₩277m margin −6.4% | −₩512m |
| Q3 2024 | ₩4.6bn | +129.4% | ₩1.3bn margin 29.0% | ₩1.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Pangen Biotech top stories 2 weeks, by number of outlets
- 1